Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf..
Please find below a statement of such trading in shares issued by Novo Nordisk.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMartin Holst Lange 2 Reason for the notification a)Position/statusExecutive Vice President, R&D and Chief Scientific Officer (CSO) b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument,
type of instrument,
Shares Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionSale of shares c)Price(s) and volume(s) Price(s)Volume(s) DKK 285.0012,000 d)Aggregated information
12,000
DKK 3,420,000.00
e)Date of the transaction2026-11-04 f)Place of the transactionNasdaq Copenhagen
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.
Contacts for further information
Company announcement No 66 / 2026
Attachment
261105_PDMR trading_MartinHolstLange
